Navigation Links
Cephalon Appoints Gerald J. Pappert as General Counsel
Date:4/30/2008

FRAZER, Pa., April 30 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Jerry Pappert has been appointed Executive Vice President and General Counsel. In this position, Mr. Pappert will manage all legal affairs for the company, including those relating to commercial and financial transactions, litigation, intellectual property and corporate and securities matters. Reporting directly to Chairman and CEO, Frank Baldino Jr., Ph.D., he will serve on the company's Executive Committee. Mr. Pappert will join the company on May 12.

"We are fortunate to have an attorney of Jerry's caliber join our leadership team," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Jerry exemplifies the professional leadership qualities we value and his strategic advice and counsel will help us navigate the increasingly intersecting environment of legal and business issues."

Mr. Pappert brings 20 years of legal experience, which includes eight years with the Commonwealth of Pennsylvania, as Attorney General from 2003 to 2005 and First Deputy Attorney General from 1997 to 2003. Since leaving the Attorney General's office, Pappert has been a partner with Ballard Spahr Andrews & Ingersoll LLP in Philadelphia where he has been a member of the Litigation Department. Prior to his tenure in Harrisburg, he conducted a commercial litigation practice within a large Philadelphia law firm.

A graduate of Villanova University, Mr. Pappert earned his Juris Doctorate from the University of Notre Dame Law School in South Bend, Indiana.

Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), TREANDA(R) (bendamustine hydrochloride) for Injection, FENTORA(R) (fentanyl buccal tablet) [C-II], PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
2. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
3. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
7. Seattle-Based Marsha Rivkin Center for Ovarian Cancer Research Appoints Nancy Sclater, Executive Director
8. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
9. InfuSystem Holdings Appoints Two New Board Members
10. KePRO Appoints Two New IT Vice Presidents
11. Bioponic Phytoceuticals Appoints Renowned Physician Dr. Barbara Nabrit-Stephens to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The Radiology ... excellence in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Fort Worth Hotel in Fort Worth, Texas. Nine awards are given out in five ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the ... The Jensie Gran Fondo of Marin. For the second year in a row, ... mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The 89th ... the winner of the 2016 National Education Policy Center Bunkum Award. We invite you ... in 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)...  The particle counters market is projected to ... 275.9 million in 2016, at a CAGR of ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical and ... growth in manufacturing industries in emerging nations are ... counters. On the other hand, technical limitations of ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
Breaking Medicine Technology: